drugset / Trial / NCT07602140

TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.

NCT07602140

Phase 2 Not yet recruiting 40 enrolled Shandong Provincial Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study is a multicenter, single-arm prospective clinical trial designed to evaluate the efficacy of TACE combined with thermal ablation, antibody-drug conjugates, immune checkpoint inhibitors, and first-line chemotherapy for the treatment of HER2 - highly expressing gastric cancer with liver metastases.

Timeline

Start
2026-08-01
Primary completion
2028-08-01
Completion
2029-08-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Disitamab Vedotin Monoclonal antibody 2.5 mg/kg Intravenous
Subject S-1 Small molecule 40 mg Oral
Subject S-1 Small molecule 60 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications